Cosentyx Continues to Ease Symptoms Through 3 Years of Use, New Trial Data Show
Treatment with Cosentyx (secukinumab) continues to be safe and to ease symptoms in people with active ankylosing spondylitis (AS) through three years of use, new data from a Phase 3 trial show. The three-year data were reported in a study, titled “Secukinumab 150/300…